Urgent.News

One page, thousands of outlets. See who else covered it.

Editions

Health & Medicine

STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

Europe pulls Tavneos over trial integrity concerns, pricing concerns over AstraZeneca's hypertension drug, and more biotech news from The Readout

STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

We haven't written up this one. STAT News has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at statnews.com →

More in Health & Medicine

More from Monday 17 August →